Takeda Pharmaceutical Co Ltd (TAK)
13.07
-0.16
(-1.21%)
USD |
NYSE |
Apr 25, 16:00
13.10
+0.03
(+0.23%)
Pre-Market: 09:15
Takeda Pharmaceutical Free Cash Flow (Quarterly): 476.74M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 476.74M |
| September 30, 2023 | 956.59M |
| June 30, 2023 | -1.289B |
| March 31, 2023 | -959.41M |
| December 31, 2022 | 2.300B |
| September 30, 2022 | 1.313B |
| June 30, 2022 | -109.09M |
| March 31, 2022 | 2.952B |
| December 31, 2021 | 2.540B |
| September 30, 2021 | 1.717B |
| June 30, 2021 | 1.138B |
| March 31, 2021 | 2.657B |
| December 31, 2020 | 1.717B |
| September 30, 2020 | 1.952B |
| June 30, 2020 | 979.32M |
| March 31, 2020 | 1.129B |
| December 31, 2019 | 562.75M |
| September 30, 2019 | 1.759B |
| June 30, 2019 | 707.93M |
| March 31, 2019 | 676.10M |
| December 31, 2018 | 544.05M |
| September 30, 2018 | 485.30M |
| June 30, 2018 | 47.75M |
| March 31, 2018 | 933.11M |
| December 31, 2017 | 563.90M |
| Date | Value |
|---|---|
| September 30, 2017 | 333.21M |
| June 30, 2017 | 422.46M |
| March 31, 2017 | 798.90M |
| December 31, 2016 | -146.74M |
| September 30, 2016 | 392.19M |
| June 30, 2016 | 336.58M |
| March 31, 2016 | -1.399B |
| December 31, 2015 | 448.64M |
| September 30, 2015 | 430.48M |
| June 30, 2015 | 25.07M |
| March 31, 2015 | 117.69M |
| December 31, 2014 | 311.74M |
| September 30, 2014 | 519.23M |
| June 30, 2014 | -273.80M |
| March 31, 2014 | 829.11M |
| December 31, 2013 | 282.76M |
| September 30, 2013 | 643.77M |
| June 30, 2013 | -1.055B |
| March 31, 2013 | |
| December 31, 2012 | |
| September 30, 2012 | |
| June 30, 2012 | |
| March 31, 2012 | |
| December 31, 2011 | |
| September 30, 2011 |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-1.289B
Minimum
Jun 2023
2.952B
Maximum
Mar 2022
1.184B
Average
1.138B
Median
Jun 2021
Free Cash Flow (Quarterly) Benchmarks
| Hoya Corp | 204.03M |
| Otsuka Holdings Co Ltd | 392.29M |
| Nxera Pharma Co Ltd | -9.318M |
| PeptiDream Inc | 21.30M |
| Stemcell Holdings Inc | -- |